MA49339A - Conjugués insuline-fc à extension oligomère - Google Patents
Conjugués insuline-fc à extension oligomèreInfo
- Publication number
- MA49339A MA49339A MA049339A MA49339A MA49339A MA 49339 A MA49339 A MA 49339A MA 049339 A MA049339 A MA 049339A MA 49339 A MA49339 A MA 49339A MA 49339 A MA49339 A MA 49339A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- oligomer extended
- extended insulin
- relates
- oligomer
- Prior art date
Links
- 239000013067 intermediate product Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164950 | 2017-04-05 | ||
| EP17208780 | 2017-12-20 | ||
| EP18151228 | 2018-01-11 | ||
| CN201810276163 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49339A true MA49339A (fr) | 2020-02-12 |
Family
ID=61868527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049339A MA49339A (fr) | 2017-04-05 | 2018-04-04 | Conjugués insuline-fc à extension oligomère |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11471537B2 (https=) |
| EP (1) | EP3606560A2 (https=) |
| JP (1) | JP2020513019A (https=) |
| CN (1) | CN110505885A (https=) |
| MA (1) | MA49339A (https=) |
| WO (1) | WO2018185131A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー／エス | 極性の組換え延長部を有するインスリン |
| CN108136043B (zh) | 2015-10-01 | 2022-09-06 | 诺和诺德股份有限公司 | 蛋白质缀合物 |
| CN110505885A (zh) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
| US20210188895A1 (en) * | 2017-10-13 | 2021-06-24 | Bonac Corporation | Single-stranded nucleic acid molecule, and production method therefor |
| CN112839681A (zh) * | 2018-10-10 | 2021-05-25 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物及其医学用途 |
| CN111433188B (zh) | 2018-12-17 | 2023-08-01 | 荣昌生物制药(烟台)股份有限公司 | 一种用于抗体药物偶联物的连接子及其应用 |
| CN111217915B (zh) * | 2019-01-08 | 2021-05-14 | 东莞太力生物工程有限公司 | GLP-1类似物Fc融合多肽及其应用 |
| EP4230216A4 (en) * | 2020-07-24 | 2025-02-19 | Jiangsu Gensciences Inc. | Insulin-fc fusion protein and application thereof |
| WO2023064711A2 (en) * | 2021-10-14 | 2023-04-20 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TWI871539B (zh) | 2021-11-15 | 2025-02-01 | 美商美國禮來大藥廠 | 可保存之調配物 |
| CN119403824A (zh) * | 2022-06-23 | 2025-02-07 | 赛诺菲 | 单链胰岛素及其Fc缀合物 |
| CN115947822B (zh) * | 2022-07-04 | 2023-08-18 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
| WO2025098472A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京拓界生物医药科技有限公司 | 融合蛋白及其医药用途 |
| WO2026024920A1 (en) * | 2024-07-24 | 2026-01-29 | Eli Lilly And Company | Fc-ACYLATED POLYPEPTIDE CONJUGATES |
| CN118955627B (zh) * | 2024-10-17 | 2025-02-07 | 山东华涛食品有限公司 | 一种混合型抑制α-葡萄糖苷酶活性的甘薯肽组合物 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE286509C (https=) | ||||
| DE257197C (https=) | ||||
| US3914252A (en) | 1971-03-15 | 1975-10-21 | Continental Oil Co | Preparation of N-iodocompounds |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2230492C (en) | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998022577A1 (en) | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| EP1352062A2 (en) | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
| PE20020908A1 (es) | 2001-03-21 | 2002-10-26 | Cell Therapeutics Inc | Produccion recombinante de polimeros polianionicos y uso de de los mismos |
| US20050233417A1 (en) | 2001-11-12 | 2005-10-20 | Cooper David N | Growth hormone variations in humans and their uses |
| GB2389115B (en) | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ATE555133T1 (de) | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| KR100594607B1 (ko) | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| WO2006081249A2 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Conjugates of biologically active proteins having a modified in vivo half-life |
| EP1843790A2 (en) | 2005-01-27 | 2007-10-17 | Novo Nordisk A/S | Insulin derivatives conjugated with structurally well defined branched polymers |
| BRPI0607775A2 (en) | 2005-02-16 | 2018-06-26 | Novo Nordisk A/S | conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| AU2006324488B2 (en) | 2005-12-12 | 2013-03-21 | Abcam Limited | Production of conjugates |
| CN101384272B (zh) | 2005-12-20 | 2013-05-01 | 杜克大学 | 用于递送具有增强的药理性质的活性剂的方法和组合物 |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| JP5256199B2 (ja) | 2006-08-07 | 2013-08-07 | テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド | アルブミン−インスリン融合タンパク質 |
| DK2074141T3 (en) | 2006-09-22 | 2016-11-28 | Novo Nordisk As | The protease resistant insulin analogues. |
| PT2094728E (pt) | 2006-10-26 | 2013-05-27 | Janssen Biotech Inc | Métodos de adaptação de anticorpos monoclonais ao ser humano |
| WO2008049711A1 (en) * | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| WO2008147456A2 (en) | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| KR20080095141A (ko) | 2007-04-23 | 2008-10-28 | 포항공과대학교 산학협력단 | 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법 |
| CN105131127B (zh) | 2007-05-30 | 2018-09-07 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| JP5314033B2 (ja) | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ |
| KR101784231B1 (ko) | 2008-06-20 | 2017-11-08 | 노파르티스 아게 | 응집이 감소된 면역글로불린 |
| US20110119848A1 (en) | 2008-07-02 | 2011-05-26 | Koninklijke Philips Electronics N.V. | V-spring configuration and end attachment assemblies therefor for use in a personal care appliance |
| UA101670C2 (ru) | 2008-07-23 | 2013-04-25 | Ханми Сайенс Ко., Лтд. | Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| MX2012003939A (es) | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| US20120276092A1 (en) * | 2009-10-29 | 2012-11-01 | Jinquan Luo | Antibody Glycosylation Variants |
| US8637637B2 (en) | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| US9783571B2 (en) | 2011-04-05 | 2017-10-10 | Warham Lance Martin | Isolation of cysteine containing peptides |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CA2873112A1 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| JP2016521701A (ja) | 2013-06-07 | 2016-07-25 | ノヴォ ノルディスク アー／エス | 成熟インスリンポリペプチドを作製するための方法 |
| CN105792851B (zh) | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| JP6620094B2 (ja) | 2013-11-26 | 2019-12-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答を調節するための組成物および方法 |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| CN106687482B (zh) | 2014-09-17 | 2022-01-25 | 诺和诺德股份有限公司 | 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体 |
| US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
| AR105616A1 (es) * | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| JP6983075B2 (ja) * | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー／エス | 極性の組換え延長部を有するインスリン |
| CA2994853C (en) | 2015-08-14 | 2023-06-27 | Rc Biotechnologies, Inc. | Covalent linkers in antibody-drug conjugates and methods of making and using the same |
| CN108136043B (zh) | 2015-10-01 | 2022-09-06 | 诺和诺德股份有限公司 | 蛋白质缀合物 |
| CN110505885A (zh) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
-
2018
- 2018-04-04 CN CN201880023755.XA patent/CN110505885A/zh not_active Withdrawn
- 2018-04-04 US US16/500,897 patent/US11471537B2/en active Active
- 2018-04-04 JP JP2019554912A patent/JP2020513019A/ja not_active Withdrawn
- 2018-04-04 WO PCT/EP2018/058550 patent/WO2018185131A2/en not_active Ceased
- 2018-04-04 MA MA049339A patent/MA49339A/fr unknown
- 2018-04-04 EP EP18715032.1A patent/EP3606560A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018185131A3 (en) | 2018-11-15 |
| EP3606560A2 (en) | 2020-02-12 |
| CN110505885A (zh) | 2019-11-26 |
| US11471537B2 (en) | 2022-10-18 |
| WO2018185131A2 (en) | 2018-10-11 |
| US20200261595A1 (en) | 2020-08-20 |
| JP2020513019A (ja) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49339A (fr) | Conjugués insuline-fc à extension oligomère | |
| MX2018005387A (es) | Variantes de fgf21. | |
| MX2019012081A (es) | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| WO2016187220A3 (en) | Anti-ror1 antibodies | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| WO2018033254A3 (en) | Rna for cancer therapy | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| WO2020076969A3 (en) | Anti-lap antibody variants and uses thereof | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| MX2026000051A (es) | Peptidos penetrantes celulares | |
| MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| WO2018154118A3 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| EP4364805A3 (en) | Novel pyridazines | |
| MY208682A (en) | Therapeutic fusion proteins | |
| WO2020039088A3 (en) | Aromatic molecules for use in the treatment of pathological conditions | |
| EP4406613A3 (en) | Immunogenic arginase peptides |